ADCT-901 is under clinical development by ADC Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ADCT-901’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ADCT-901 overview
ADCT-901 is under development for the treatment of solid tumors including platinum-resistant ovarian cancer, bile duct cancer (cholangiocarcinoma), fallopian tube cancer, prostate cancer, renal cell carcinoma and triple-negative breast cancer (TNBC). The drug candidate is a monoclonal antibody drug conjugate which targets cells expressing kidney associated antigen 1 (KAAG1). It is administered through intravenous route.
ADC Therapeutics overview
ADC Therapeutics is a biotechnology company that develops antibody-drug conjugates (ADCs) to treat hematologic malignancies and solid tumors. It offers Zynlonta, a CD-19-directed antibody for treatment of e B-cell lymphoma in adult patients. The company is provides Loncastuximab Tesirine (Lonca)and Camidanlumab Tesirine (Cami). ADC Therapeutics develops ADCT-602 drug for B-cell acute lymphoblastic leukemia, ADCT-601 targeting AXL in solid tumors, ADCT-901 against ovarian, triple-negative breast cancer and advanced solid tumors and ADCT-701 drug targeting DLK-1 in neuroblastoma, hepatocellular carcinoma, small cell lung cancer and myeloid leukemia. The company has operations in London, the UK and New Providence, and San Mateo, the US. ADC Therapeutics is headquartered in Lausanne, Switzerland.
For a complete picture of ADCT-901’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
